Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $34.00

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.00.

Several brokerages have commented on ARCT. Roth Mkm started coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Citigroup lowered their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright cut their target price on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Finally, Wall Street Zen downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds have recently made changes to their positions in ARCT. Kennedy Capital Management LLC increased its stake in Arcturus Therapeutics by 4.9% during the second quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 544 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,567 shares during the period. Bank of America Corp DE increased its position in shares of Arcturus Therapeutics by 0.7% during the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock valued at $3,805,000 after purchasing an additional 2,098 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 2,313 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ:ARCT opened at $8.30 on Monday. The stock’s 50-day moving average is $7.13 and its 200-day moving average is $11.66. The company has a market cap of $235.80 million, a P/E ratio of -3.37 and a beta of 2.39. Arcturus Therapeutics has a 52-week low of $5.85 and a 52-week high of $24.17.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.